Matthew Frank, MD, PhD, on Investigation CD22 CAR for LBCL After CD19 Relapse

The assistant professor of BMT and cellular therapy discussed updated safety and efficacy data on CD22 CAR T-cell therapy.

“This appears to be a very promising emerging option for folks. We're excited about the high response rates, the durable response rates, and the relatively lower frequency of grade 3 events. So overall, we'revery excited about this CD22 CAR therapy.”

CD22 CAR, an investigational autologous CD22-directed chimeric antigen receptor T-cell (CAR-T) therapy, has produced high response rates in patients with large B-cell lymphoma (LBCL) who previously relapsed after receiving CD19-directed CAR-T therapy or who had CD19-negative disease. Data on the therapy, from a phase 1 clinical trial (NCT04088890), were presented at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19, 2023, by Matthew J. Frank, MD, PhD, assistant professor of medicine, division of BMT & Cellular Therapy, Division of Stanford Cancer Institute.

CGTLive spoke with Frank to learn more about the updated data from the trial. He discussed the unmet need in patients with LBCL that relapse after CAR T-cell therapy and the manageable safety profileand promising efficacy signals seen with CD22 CAR.

Frank MJ, Sahaf B, Baird J, et al. CD22 CAR T cell therapy induces durable remissions in patients with large B cell lymphoma who relapse after CD19 CAR T cell therapy. Presented at: 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. February 15-19, 2023; Orlando, FL. Abstract 2

Related Videos
Natalie Goedeker, CPNP, on Supporting Gene Therapy’s Ascendance in Muscular Dystrophies
Angela Genge, MD, FRCPC, eMBA, on Targeting STMN2 to Rescue Neurons in ALS
Related Content
© 2023 MJH Life Sciences

All rights reserved.